Palo Alto, CA, June 14, 2016 – enlightenbio LLC, today announced the publication of its first NGS Process Report. This new report details market trends, unmet needs and challenges, and an extensive ecosystem analysis of the NGS analysis and interpretation space. This report is unique, in that it is not a predictive market research report, but rather builds on the data gathered from the many end-user interviews and the data available in the scientific literature.
The NGS process space is extremely busy with many commercial players that provide sequencing reagents, instruments, and analysis solutions. To decipher the NGS process and its components, a systematic analysis approach was undertaken rooted in the following questions: who are the key commercial companies in this process, who are the end-users and what are their unmet needs and challenges, and – when researching the analysis and interpretation side of the equation – what challenges need the commercial life science product providers address, and who addresses them how?
For a limited time only, apply Promo Code FIRST10 and get 10% off when purchasing the report – valid until July 31, 2016.
Download Table of Contents to learn more about the report specifics.
The extensive analysis of this space highlights that as the sequencing technology has matured, the challenges have shifted toward data explosion and computing, data interpretation to gather and report actionable information, and information management.
Our specific analysis identified the obvious top players which includes Illumina on the instruments side (and to some extent on the reagents side), Thermo Fisher Scientific, and Pacific Biosciences; Illumina also offers a data analysis and interpretation solution via BaseSpace. Agilent technologies, Qiagen, and Thermo Fisher Scientific are the main actors on the reagents side, while on the analysis side we observe several providers that are strong in different areas of data analysis and interpretation. DNAnexus and Seven Bridges Genomics have emerged as open and flexible platforms for data analysis, Bluebee, Genalice, and Edico Genome as alternatives enabling fast DNA processing. On the data interpretation side we have several noteworthy companies such as Congenica, Ingenuity (Qiagen), Omicia, Station X, or WuXi NextCODE offering elegant analysis solutions, with Congenica, Ingenuity, Omicia, and WuXi NextCODE also being strong on the clinical data interpretation side. Alongside these established companies, we should not overlook the significant impact of open source tools that command a sizable share of the data analysis volume (~68% of all users still use in-house or open source tools for their analyses – some as standalone solutions and some in combination with commercially available offerings), such as the Broad Institute Scientific Community Software and Sanger Institute Tools and Software made available to the entire community.
Our data is substantiated with an analysis of the published NGS/sequencing literature, 28 interviews (19 end-users and nine industry representative interviews – for details see the figure below) highlighting product preferences for sample preparation and sample sequencing, customer/end-users unmet needs and challenges, and the brand perception users have for the different supplier companies and their products, plus an extensive comparative analysis of key players in the sequence data analysis and interpretation space.
This 111 page NGS Process Report consists of 23 Figures, 39 Tables, and 17 company profiles (Agilent Technologies, Bina Technologies, Bluebee, CLC Bio (Qiagen), Congenica, DNAnexus, Edico Genome, Genalice, BaseSpace (Illumina), Ingenuity Systems (Qiagen), New England Biolabs, Omicia, Qiagen, Seven Bridges Genomics, Station X, Thermo Fisher Scientific, and WuXi NextCODE).
We are very excited about this major report release that represents a significant milestone for us in our mission to bring up-to-date and concise information with translatable value to our customer community. With the release of the NGS Process Report, we have also revamped our enlightenbio website. We hope you like it as much as we do and will find value in the updated content.